Trials / Unknown
UnknownNCT04274101
Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment
Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment, Retrospective Cohort
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 900 (estimated)
- Sponsor
- Hospital de Niños R. Gutierrez de Buenos Aires · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Chagas disease is caused by parasite Trypanosoma Cruzi. In Argentina, there is an estimated of 1.600.000 infected people. Due to migration phenomenon, most cases live in urban areas without vectorial transmission. Pharmacological treatment is given to prevent development of cardiac and gastrointestinal sequelae. There are two available drugs for this disease; Nifurtimox and Benznidazole. They both has proven efficacy for acute face treatment, with different security profiles. There are not enough adequate studies comparing both drugs made in a large number of subjects. Investigators will study 900 patients treated with both drugs and compare security and efficacy in a retrospective cohort.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Clinical Manifestations | Clinical manifestations in patients treated with Nifurtimox and Benznidazole |
| DIAGNOSTIC_TEST | Serologic response | Serologic response in patients treated with Nifurtimox and Benznidazole |
| DIAGNOSTIC_TEST | Direct method | Direct method tests in patients treated with Nifurtimox and Benznidazole |
| BEHAVIORAL | Adverse events | Adverse events in patients treated with Nifurtimox and Benznidazole |
Timeline
- Start date
- 2018-06-01
- Primary completion
- 2020-08-01
- Completion
- 2025-02-01
- First posted
- 2020-02-18
- Last updated
- 2023-03-01
Locations
1 site across 1 country: Argentina
Source: ClinicalTrials.gov record NCT04274101. Inclusion in this directory is not an endorsement.